Evidence map›Paper›PMID 38074635›Full record

ArticleFrontiers in oncology2023

Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.

Yang Li, Jingjiao Zhang, Zhengang Cai, Xue Gao, Lina Zhang, Zhi Lu, Xiaojie Wang, Peiyao Yu, Jia Li, Fengqi Fang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yang Li *Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Jingjiao Zhang *Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Zhengang CaiDepartment of Breast Surgery, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Xue GaoDepartment of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Lina ZhangImaging and Nuclear Medicine Department, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Zhi LuNuclear Medicine Department, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Xiaojie WangDepartment of Radiotherapy, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Peiyao YuDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Jia LiDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Fengqi FangDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
First Affiliated Hospital of Dalian Medical University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of metastasis and poorer overall survival (OS) due to HER2 gene overexpression/amplification. Although anti-HER2 targeted therapy has shown survival benefits in HER2-positive advanced breast cancer (ABC) patients, long-term treatment often leads to drug resistance, complicating further treatment options. RC48, an antibody-drug conjugate (ADC), combines the benefits of antibody targeting with the cytotoxic effects of a small molecule drug. Case report: We present a case involving a female patient with HER2-positive ABC who developed drug resistance and disease progression following multi-line anti-HER2 targeted therapy. In this instance, RC48 exhibited anti-tumor activity in an ABC patient resistant to HER2-targeted therapy. After eight treatment cycles with 120 mg of RC48, the tumor size decreased and stabilized. Conclusion: This case report underscores the potential clinical value of RC48 as a promising treatment alternative for patients resistant to HER2 targeted therapies.

Indexed as

advanced breast cancercase reportDisitamab Vedotin (RC48)human epidermal growth factor receptor 2targeted therapytumor resistance

Identifiers

PMID38074635
PMCPMC10704599
OpenAlexW4388973328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.